apsgb.co.uk Report : Visit Site

Technical data of the apsgb.co.uk

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host apsgb.co.uk. Currently, hosted in United Kingdom and its service provider is IAAS VLAN .

the related websites

imperial.ac.uk jpag.org port.ac.uk nhs.uk telegraph.co.uk crickweb.co.uk premierbodyshops.co.uk dailymail.co.uk theorganicpharmacy.com 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Microsoft-IIS/8.5 containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

the academy of pharmaceutical sciences 'promoting the pharmaceutical sciences' member login join aps home my account about us events focus groups the board awards sponsorship resources useful links flex pharma to stop two neuromuscular disease trials over safety concerns..... fda approves roche's avastin plus chemotherapy for ovarian cancer after surgery..... recipharm agrees to acquire sanofi cmo business in uk..... albireo gets fda rare pediatric disease designation for rare liver disease treatment a4250..... merck's keytruda snags i-o's first cervical cancer nod to back up hpv fighter gardasil..... celeb-happy allergan adds helen hunt, trista sutter and more to alzheimer's push..... want to help patients? get rid of drug rebates, hhs chief says..... what?s a move to new jersey worth? for teva?s u.s. headquarters, $40m in tax breaks..... recipharm to buy sanofi inhalation contract business and plant in u.k. for $60m..... merck's keytruda secures fda approval for advanced cervical cancer..... ascletis' ganovo gets cfda approval for treatment of viral hepatitis c..... grnenthal begins phase iii trials in complex regional pain syndrome..... glaxosmithkline to pass $10b in 2024 vaccine sales, with merck, sanofi and pfizer rounding out the top 4: report..... glaxosmithkline bids adieu to vaccines president luc debruyne as executive overhaul continues..... sanofi, translate bio ink mrna vaccine r&d; deal worth up to $805m..... advaxis doses first patient with adxs-neo cancer immunotherapy..... astrazeneca, eli lilly terminate clinical trials of alzheimer's disease treatment lanabecestat..... glaxosmithkline to pass $10b in 2024 vaccine sales, with merck, sanofi and pfizer rounding out the top 4: report..... after setting aside $200m, endo settles 1,300 testosterone liability lawsuits..... sun pharma finally free of fda restrictions on its key plant in india..... merck rebuts petition urging scotus to ignore fosamax appeal..... sprout's old ceo is back, and she's got some new marketing ideas for female libido drug addyi..... glaxosmithkline bids adieu to vaccines president luc debruyne as executive overhaul continues..... sanofi pasteur to buy license of translate's mrna technology in $805m deal..... bridgebio pharma to acquire late stage therapy for ultra-rare disorder from alexion..... allergan taps #weallgrow influencers for help steering latinas to coolsculpting..... doctors are coming around to teva's austedo as td drugs get more play: analyst..... wuxi biologics to build u.s. plant as it rapidly moves beyond its china base..... old ceo, new chairman? some allergan investors want pyott to come back: report..... fda approves abbvie and roche's venclexta-rituximab combo for cll..... alnylam's lumasiran yields positive results in phase 1/2 hyperoxaluria study..... fda accepts cellenkos? ind to begin clinical trial of ck0801 for bone marrow failure syndromes..... astrazeneca gets ec nod for tagrisso as first-line treatment for egfr-mutated nsclc..... fda beefs up generics-use push with radio psas..... after a stormy year, outcome health says it's ready, steady and primed with new board members..... gsk?s message to college-bound kids and their parents: get meningitis b vaccine..... trust pharma? not so much, annual survey shows, with biggest loss ever..... what?s in a tweet? sanofi's viral roseanne retort draws kudos, followers and flak..... fiercepharmaasia?china?s data rule, biocon-mylan?s lantus copy, eisai-biogen alzheimer?s readout..... pfizer wins appeal of 84m fine in u.k. over 2,600% price hike..... merck impresses nice with keytruda data?and discounts?cueing up a cdf switch..... genentech?s rituxan gets fda approval to treat pemphigus vulgaris..... uk's mhra, chm adopt positive opinion on approval of alliance pharma's diclectin..... oncologie commences operations in boston and shanghai..... saunders supporter carl icahn joins activist party at allergan?just as rebels push for a c-level overhaul..... parp battle heats up as pfizer nabs priority review for talazoparib in breast cancer..... abbvie's humira, merck's keytruda and more: the top 10 drugs of 2024..... pfizer to invest $600m in biotechnology and other growth companies..... abbvie?s upadacitinib succeeds in phase 3 trial in rheumatoid arthritis..... sirnaomics secures $25m to expand clinical programs of anti-fibrosis and anti-cancer rnai therapeutics..... axovant, oxford biomedica sign $842.5m parkinson?s disease deal..... fda wants social media giants to help crack down on illegal opioid marketers..... eyeing the most lucrative vaccine market, sutrovax nabs $85m and moncef slaoui as chairman..... in may tv spending, sunovion jumps to 2nd, but abbvie easily keeps top spot..... roche's multiple sclerosis drug ocrevus lowered patients' vaccine responses: study..... with its case count climbing, johnson & johnson faces major test in talc defense..... ceo: win or lose on ampyra patents, acorda reps are safe with parkinson's prospect..... ovid ceo jeremy levin chides pharma for using tax savings for buybacks, not r&d.....; roche?s hemlibra gets fda priority review for new haemophilia a indication..... hookipa, gilead to jointly develop therapeutics against hiv and hepatitis b infections..... nimbus therapeutics raises $65m in new capital to expand discovery efforts..... rss newsfeed.... welcome to the academy of pharmaceutical sciences the academy of pharmaceutical sciences (aps) is the uk-based professional membership body for pharmaceutical scientists. we represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the pharmaceutical science sector. latest news call for nominations for the eminent fellowship and fellowship of the academy of pharmaceutical sciences (aps) the aps is proud to announce a call for this years nominations for two awards, the eminent fellowship (nominated by an aps member) fellowship of the academy (self-nominated by an aps member) these awards recognise and reward science from all sectors where pharmaceutical scientists work. the eminent fellowship will be presented at a social networking event held on thursday 6th september followed by this years premier uk pharmaceutical sciences conference, aps@fip conference in 2018 which will take place in glasgow on the 7th september 2018. for more information, click here professional recognition for pharmaceutical science degrees the academy of pharmaceutical sciences (aps) is delighted to announce that the pharmaceutical science course at the university of greenwich has become the first aps accredited course having successfully completed the accreditation process set up by the academy towards the end of 2017. this is the first time that a pharmaceutical science course has been accredited in the united kingdom and it is also, we believe, a world first. achieving accreditation gives assurance to students and employers that the course meets the high standards required by the academy and that these standards will be maintained throughout the 5-year period of accreditation. aps believes that the accreditation process will raise the profile of pharmaceutical sciences in both academia and industry. the discipline is key in the discovery, development and manufacture of new medicines and as such is central to government initiatives to encourage the pharmaceutical industry to maintain and strengthen its strong base here in the uk. the academy will continue to work with other stakeholders to build the science base for the ultimate benefit of patients. aps events overview the aps has developed an exciting and informative programme for our events in 2018. dont forget to make a note of aps@fip, linking with the 78th fip world congress of pharmacy and pharmaceutical science conference. please take a look at our programme, with event summaries, below: nanomedicines for the delivery of biologics 18 july 2018 - university of reading under the auspices of aps, with

URL analysis for apsgb.co.uk

http://www.apsgb.co.uk//javascript:hidecontactpage()
https://www.apsgb.co.uk/events/20180718/default.asp
http://www.apsgb.co.uk/resources/default.asp
http://www.apsgb.co.uk//javascript:hidesubpage()
http://www.apsgb.co.uk/awards/nominations.asp
http://www.apsgb.co.uk///situations_vacant/advertise.asp
http://www.apsgb.co.uk/awards/
http://www.apsgb.co.uk///privacypolicy
https://www.apsgb.co.uk/events/20180907/default.asp
http://www.apsgb.co.uk/events/default.asp
http://www.apsgb.co.uk/aboutus/
https://www.apsgb.co.uk/my_account/default.asp
http://www.apsgb.co.uk/theboard/
http://www.apsgb.co.uk//mailto:[email protected]
http://www.apsgb.co.uk/usefullinks/default.asp
pfizer.co.uk
astrazeneca.co.uk
mylan.co.uk

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Error for "apsgb.co.uk".

the WHOIS query quota for 2600:3c03:0000:0000:f03c:91ff:feae:779d has been exceeded
and will be replenished in 196 seconds

WHOIS lookup made at 20:24:11 15-Aug-2017

--
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:

Copyright Nominet UK 1996 - 2017.

You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at http://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.

  REFERRER http://www.nominet.org.uk

  REGISTRAR Nominet UK

SERVERS

  SERVER co.uk.whois-servers.net

  ARGS apsgb.co.uk

  PORT 43

  TYPE domain

DISCLAIMER
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:
Copyright Nominet UK 1996 - 2017.
You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at http://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.

  REGISTERED no

DOMAIN

  NAME apsgb.co.uk

NSERVER

  DNS2.4THENET.COM 173.192.101.194

  DNS3.4THENET.COM 193.33.179.204

  DNS5.4THENET.COM 81.95.158.50

  DNS4.4THENET.COM 52.64.171.200

  DNS7.4THENET.COM 119.81.97.170

  DNS1.4THENET.COM 23.236.59.22

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .